Similar to Rap’s inhibitory effect on mTOR/HIF1α/AMPK signaling, Met treatment abrogated FD/LCS-promoted expression of mTORC1 (Figure 6(a-1)) and HIF1α (Figure 6(a-2)), and sustained FD/LCS-promoted AMPK expression (Figure 6(a-3)) compared with their untreated FD and control counterparts. Here, LRPAP1 is linked to Fabry disease.